CHEK2 and breast cancer: Pyrazole-benzimidazole derivatives are novel potent active Chk2 inhibitors were described by Galal et al. Out of the synthesized compounds, compound 288 was reported as the most potent effects as Chk2 inhibitors with cytotoxic properties besides their potentiation effects on the cytotoxicity of both cisplatin and doxorubicin, and showed marked antitumor activity as single agent in breast cancer–bearing animals [193].